光滑念珠菌感染继发侵袭性念珠菌病长期治疗后卡泊芬净耐药性的产生。
Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.
作者信息
Thompson George R, Wiederhold Nathan P, Vallor Ana C, Villareal Nyria C, Lewis James S, Patterson Thomas F
机构信息
Department of Internal Medicine, Division of Infectious Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
出版信息
Antimicrob Agents Chemother. 2008 Oct;52(10):3783-5. doi: 10.1128/AAC.00473-08. Epub 2008 Aug 1.
Abstract
We report a case of Candida glabrata invasive candidiasis that developed reduced susceptibility to caspofungin during prolonged therapy. Pre- and posttreatment isolates were confirmed to be isogenic, and sequencing of hot spots known to confer echinocandin resistance revealed an F659V substitution within the FKS2 region of the glucan synthase complex.
摘要
我们报告了1例光滑念珠菌侵袭性念珠菌病病例，该病例在长期治疗期间对卡泊芬净的敏感性降低。治疗前和治疗后的分离株经确认是同基因的，对已知赋予棘白菌素耐药性的热点区域进行测序，结果显示葡聚糖合酶复合体的FKS2区域内有一个F659V替换。
相似文献
1
Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.
Antimicrob Agents Chemother. 2008 Oct;52(10):3783-5. doi: 10.1128/AAC.00473-08. Epub 2008 Aug 1.
2
The Gastrointestinal Tract Is a Major Source of Echinocandin Drug Resistance in a Murine Model of Candida glabrata Colonization and Systemic Dissemination.
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01412-17. Print 2017 Dec.
3
Evolutionary dynamics in gut-colonizing Candida glabrata during caspofungin therapy: Emergence of clinically important mutations in sphingolipid biosynthesis.
PLoS Pathog. 2024 Sep 9;20(9):e1012521. doi: 10.1371/journal.ppat.1012521. eCollection 2024 Sep.
4
Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata.
PLoS Pathog. 2012;8(5):e1002718. doi: 10.1371/journal.ppat.1002718. Epub 2012 May 17.
5
Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
Antimicrob Agents Chemother. 2012 May;56(5):2435-42. doi: 10.1128/AAC.06369-11. Epub 2012 Feb 21.
6
Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.
Antimicrob Agents Chemother. 2008 Jun;52(6):2263-5. doi: 10.1128/AAC.01568-07. Epub 2008 Mar 31.
7
In vitro antifungal susceptibility of Candida glabrata to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infection.
Antimicrob Agents Chemother. 2014 Jul;58(7):3646-9. doi: 10.1128/AAC.02666-13. Epub 2014 Apr 14.
8
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.
Antimicrob Agents Chemother. 2008 Jul;52(7):2305-12. doi: 10.1128/AAC.00262-08. Epub 2008 Apr 28.
9
Spontaneous Mutational Frequency and Mutation Rates Vary by Echinocandin Agent against .
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01692-18. Print 2019 Jan.
10
FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.
Antimicrob Agents Chemother. 2010 Dec;54(12):5042-7. doi: 10.1128/AAC.00836-10. Epub 2010 Sep 13.
引用本文的文献
1
The yEvo Mutation Browser: Enhancing student understanding of experimental evolution and genomics through interactive data visualization.
bioRxiv. 2025 Jul 22:2025.07.18.665463. doi: 10.1101/2025.07.18.665463.
2
The Effect of Bark on Oral Candidiasis Caused by and Isolated from a Pediatric Oral Infection as Comparison to Azole Antifungal.
Clin Cosmet Investig Dent. 2025 Jul 14;17:285-292. doi: 10.2147/CCIDE.S527034. eCollection 2025.
3
Monitoring of biofilm inhibition by using real-time impedance-based technology.
Curr Med Mycol. 2024 Nov 16;10. doi: 10.22034/cmm.2024.345240.1541. eCollection 2024.
4
Antifungal drug resistance in Candida glabrata: role of cellular signaling and gene regulatory networks.
FEMS Yeast Res. 2025 Jan 30;25. doi: 10.1093/femsyr/foaf025.
5
Hotspot gene conversion between FKS1 and FKS2 in echinocandin resistant Candida glabrata serial isolates.
NPJ Antimicrob Resist. 2025 Apr 17;3(1):31. doi: 10.1038/s44259-025-00102-6.
6
Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways.
Pharmaceuticals (Basel). 2025 Mar 4;18(3):364. doi: 10.3390/ph18030364.
7
: Multidrug Resistance and Increased Virulence in a Major Opportunistic Fungal Pathogen.
Curr Fungal Infect Rep. 2012 Jun;6(3):154-164. doi: 10.1007/s12281-012-0091-0.
8
Anidulafungin is a useful surrogate marker for predicting susceptibility to rezafungin among five species using CLSI methods and interpretive criteria.
J Clin Microbiol. 2025 Feb 19;63(2):e0112924. doi: 10.1128/jcm.01129-24. Epub 2025 Jan 22.
9
Fighting Emerging Caspofungin-Resistant Species: Mitigating 1-Mediated Resistance and Enhancing Caspofungin Efficacy by Chitosan.
Antibiotics (Basel). 2024 Jun 22;13(7):578. doi: 10.3390/antibiotics13070578.
10
Two promising -derived antifungal lipopeptide leads AF and AF and their combined effect with fluconazole on the biofilms.
Front Pharmacol. 2024 Apr 19;15:1334419. doi: 10.3389/fphar.2024.1334419. eCollection 2024.
本文引用的文献
1
Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.
Antimicrob Agents Chemother. 2008 Jun;52(6):2263-5. doi: 10.1128/AAC.01568-07. Epub 2008 Mar 31.
2
Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
Clin Infect Dis. 2007 Oct 1;45(7):883-93. doi: 10.1086/520980. Epub 2007 Aug 29.
3
Anidulafungin versus fluconazole for invasive candidiasis.
N Engl J Med. 2007 Jun 14;356(24):2472-82. doi: 10.1056/NEJMoa066906.
4
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.
Lancet. 2007 May 5;369(9572):1519-1527. doi: 10.1016/S0140-6736(07)60605-9.
5
Serum differentially alters the antifungal properties of echinocandin drugs.
Antimicrob Agents Chemother. 2007 Jun;51(6):2253-6. doi: 10.1128/AAC.01536-06. Epub 2007 Apr 9.
6
Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase.
Antimicrob Agents Chemother. 2007 May;51(5):1876-8. doi: 10.1128/AAC.00067-07. Epub 2007 Feb 26.
7
In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera.
Antimicrob Agents Chemother. 2007 May;51(5):1616-20. doi: 10.1128/AAC.00105-07. Epub 2007 Feb 16.
8
In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.
Antimicrob Agents Chemother. 2006 Nov;50(11):3926-8. doi: 10.1128/AAC.00538-06. Epub 2006 Aug 28.
9
Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility.
Antimicrob Agents Chemother. 2006 Aug;50(8):2892-4. doi: 10.1128/AAC.00349-06.
10
Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin.
Pharmacotherapy. 2006 Jun;26(6):877-80. doi: 10.1592/phco.26.6.877.
Zotero 插件